Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Open access
Costa, Carlota, Molina, Miguel Angel, Drozdowskyj, Ana, Giménez-Capitán, Ana, Bertran-Alamillo, Jordi, Karachaliou, Niki, Gervais, Radj, Massuti, Bartomeu, Wei, Jia, Moran, Teresa, Majem, Margarita, Felip, Enriqueta, Carcereny, Enric, Garcia-Campelo, Rosario, Viteri, Santiago, Taron, Miquel, Ono, Mayumi, Giannikopoulos, Petros, Bivona, Trever, Rosell, Rafael · 2014 · Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: Concomitant genetic alterations could account for transient clinical responses to tyrosine kinase inhibitors of the EGF receptor (EGFR) in patients harboring activating EGFR mutations. Experimental Design: We have evaluated the impact of pretreatment somatic EGFR T790M mutations, TP53 mutations, and Bcl-2 interacting mediator of cell death (BCL2L11, also known as BIM) mRNA expression in 95 patients with EGFR-mutant non–small-cell lung cancer (NSCLC) included in the EURTAC trial (trial registration: NCT00446225). Results: T790M mutations were detected in 65.26% of patients using our highly sensitive method based on laser microdissection and peptide-nucleic acid-clamping PCR, which can detect the mutation at an allelic dilution of 1 in 5,000. Progression-free survival (PFS) to erlotinib was 9.7 months for those with T790M mutations and 15.8 months for those without, whereas among patients receiving chemotherapy, it was 6 and 5.1 months, respectively (P < 0.0001). PFS to erlotinib was 12.9 months for those with high and 7.2 months for those with low/intermediate BCL2L11 expression levels, whereas among chemotherapy-treated patients, it was 5.8 and 5.5 months, respectively (P = 0.0003). Overall survival was 28.6 months for patients with high BCL2L11 expression and 22.1 months for those with low/intermediate BCL2L11 expression (P = 0.0364). Multivariate analyses showed that erlotinib was a marker of longer PFS (HR = 0.35; P = 0.0003), whereas high BCL2L11 expression was a marker of longer PFS (HR = 0.49; P = 0.0122) and overall survival (HR = 0.53; P = 0.0323). Conclusions: Low-level pretreatment T790M mutations can frequently be detected and can be used for customizing treatment with T790M-specific inhibitors. BCL2L11 mRNA expression is a biomarker of survival in EGFR-mutant NSCLC and can potentially be used for synthetic lethality therapies. Clin Cancer Res; 20(7); 2001–10. ©2014 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-2233

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

See all 234

Metadata

Authors
Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., Majem, M., Felip, E., Carcereny, E., Garcia-Campelo, R., Viteri, S., Taron, M., Ono, M., Giannikopoulos, P., Bivona, T., & Rosell, R.
Affiliations
  • University of California, San Francisco (US)
  • Authors' Affiliations: 1Pangaea Biotech, Barcelona, Spain; 2Hospital Sant Pau, Barcelona, Spain; 3Hospital Vall d'Hebron, Barcelona, Spain; 4Molecular Oncology Research (MORe) Foundation, Barcelona, Spain; 5Pivotal, Madrid; 6Hospital General de Alicante, Alicante, Spain; 7Catalan Institute of Oncology, Badalona, Barcelona, Spain; 8Complejo Hospitalario Universitario, La Coruña, Spain; 9Centre François Baclesse, Caen, France; 10Drum Tower Hospital, Nanjing, China; 11Kyushu University, Fukuoka, Japan; 12Cancer Therapeutics Innovation Group, New York, New York, USA; and 13Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA
Corresponding author
Rosell, Rafael
Venue
Clinical Cancer Research
Published
2014-03-31
Volume
20
Issue
7
Pages
2001-2010
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2167934111
Cited by
229
References
37
Citations by year
2026: 4 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 15 · 2021: 12 · 2020: 9 · 2019: 24 · 2018: 28 · 2017: 31 · 2016: 24 · 2015: 44 · 2014: 21
FWCI
32.11
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
T790M mutation, BCL2L11, EGFR-mutant non-small cell lung cancer, erlotinib, chemotherapy, TP53 mutation, progression-free survival, overall survival, predictive biomarkers, tyrosine kinase inhibitors
MeSH terms
Erlotinib Hydrochloride, Bcl-2-Like Protein 11, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Membrane Proteins, Middle Aged, Mutation, Proto-Oncogene Proteins, Quinazolines, RNA, Messenger, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease-Free Survival, Apoptosis Regulatory Proteins, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2233
The paper
Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., Majem, M., Felip, E., Carcereny, E., Garcia-Campelo, R., Viteri, S., Taron, M., Ono, M., Giannikopoulos, P., Bivona, T., & Rosell, R. (2014). The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.